王領(華南理工大學生物科學與工程學院副教授)

王領(華南理工大學生物科學與工程學院副教授)

本詞條是多義詞,共6個義項
更多義項 ▼ 收起列表 ▲

王領,男,中共黨員,博士華南理工大學生物科學與工程學院副教授。

基本介紹

  • 中文名:王領
  • 畢業院校:中山大學
  • 學位/學歷:博士
  • 職業:教師
  • 專業方向:藥物化學
  • 籍貫:安徽宿州市
  • 任職院校:華南理工大學
人物經歷,學術成果,學術兼職,研究方向,科研項目,發表論文,發明專利,

人物經歷

2014年獲中山大學藥物化學博士學位。2014.08至今,華南理工大學生物科學與工程學院青年教師、師資博士後。

學術成果

近五年來一直從事新藥開發基礎和套用研究,包括(1)藥物分子設計方法學研究及其套用(如誘導體系藥物設計方法、優勢藥效片段藥物設計方法、機器學習藥物設計方法等);(2)基於mTOR和CDK激酶靶向抗癌藥物分子設計、合成、生物學篩選及分子機制;(3)大數據驅動的藥物活性網路預測平台構建及開發(如mTOR Predictor預測系統開發,http://rcdd.sysu.edu.cn/mtor/);(4)蛋白質結構改造、功能最佳化及生物大分子功能模擬(如半乳糖酶催化位點功能改造)。在同行評議主流期刊(如Journal of ChemicalInformation and Modeling,Antimicrobial Agents and Chemotherapy, MedicinalChemistry Communications, Scientific Reports, BBA-General Subjects, Plos one,Molecular Diversity, STEROIDS)發表文章17篇。申請新藥相關發明專利三項,授權兩項。

學術兼職

擔任New Journal of Chemistry和Journal of Molecular Modeling雜誌審稿人。

研究方向

藥物分子設計、藥物化學、計算化學生物學
從事以化學、生物、藥學、計算機科學為基礎的藥物分子設計新興交叉領域,結合實驗學科(乾濕結合)套用於:
(1)靶向抗癌和降血脂藥物的設計合成及活性研究;
(2)藥物重定向研究;
(3)基於氫氘交換質譜和蛋白模擬的藥物蛋白相互作用研究;
(4)網路藥理學平台與ADMET預測系統開發。

科研項目

1.中央高校基本科研業務費面上項目:基於優勢藥效片段組裝的新型mTOR抑制劑設計合成及活性研究;
2.青年教師科研啟動項目:基於配體-靶標網路的降血脂藥物預測平台建設;
3.博士後面上項目:基於優勢片段組裝的新型mTOR抑制劑發現與活性研究

發表論文

  1. LingWang, Xiu Le, Long Li, YingchenJu,Zhongxiang Lin, QiongGu and Jun Xu.Discovering New Agents Active againstMethicillin-resistant Staphylococcus aureus with Ligand-based Approaches.J. Chem. Inf. Model.2014, 54 (11),3186–3197.
  2. Ling Wang, Qiong Gu, Xuehua Zheng, Jiming Ye, ZhihongLiu, Jiabo Li, Xiaopeng Hu, Arnold T. Hagler, and Jun Xu.Discovery of NewSelective Human Aldose Reductase Inhibitors through Virtual Screening MultipleBinding Pocket Conformation.J. Chem. Inf.Model.2013,53,2409-2422.
  3. LingWang, Lei Chen, Zhihong Liu, Minghao Zheng,QiongGu and Jun Xu.Predicting mTOR Inhibitors with a ClassifierUsing Recursive Partitioning and Naïve Bayesian Approaches.Plos One2014, 9(5): e95221.
  4. Ling Wang, Lei Chen, Miao Yu, Li-Hui Xu, Bao Cheng, Yong-Sheng Lin, QiongGu,Xian-Hui He and Jun Xu. Discovering new mTOR inhibitors for cancer treatmentthrough virtual screening methods and in vitro assays.Scientific Reports,2015 (Minor revision).
  5. Wei Zhang,Ling Wang, LipingZhang, WenLi Chen, Xinying Chen, MinyuXie, Guangmei Yan, Xiaopeng Hu, Jun Xu,Jingxia Zhang.Synthesis and biologicalevaluation of steroidal derivatives as selective inhibitorsofAKR1B10.STEROIDS2014, 86, 39-44. (Co-first author)
  6. Bo Xu#,Ling Wang#, Lorenzo González-Molleda#, Yan Wang, Jun Xu andYan Yuan.Antiviral Activity of (+)-Rutamarin against KSHV by InhibitingCatalytic Activity of Human Topoisomerase II.Antimicrob. Agents.Chemother.2014,58,563-573. (Co-first author)
  7. Yingying Cao,Ling Wang, ZhongxiangLin, Fengyin Liang, Zhong Pei, Jun Xu and QiongGu.Dehydroabietylamine derivatives asmultifunctional agents for the treatment of Alzheimer's disease.Med. Chem. Commun.2014, 5, 1736-1743.(Co-first author)
  8. Yi-NingDong#,Ling Wang#, Qiong Gu, Haiqin Chen,Xiaoming Liu, Yuanda Song, Wei Chen, Arnold T. Hagler, Hao Zhang, and Jun Xu.OptimizingLactose Hydrolysis by Computer-guided Modification of the Catalytic Site of aWild-type Enzyme,MolecularDiversity2013, 17, 371-382. (Co-first author)
  9. Lei Chen,Ling Wang, QiongGu and Jun Xu.An insilico protocol for identifying mTOR inhibitors from natural products.Molecular Diversity2014, 18, 841-852.
  10. YaliLi,Ling Wang, Zhihong Liu,Chanjuan Li, Jiake Xu, QiongGu,Jun Xu.PredictingSelective Liver X ReceptorβAgonistsUsing Multiple Machine Learning Methods.Mol. BioSyst.2015, 11(5):1241-50.
  11. Ying Ying Cao,Ling Wang, Hu Ge, Xi Lin Lu, Zhong Pei, QiongGu,Jun Xu.SalvianolicAcid A, a PolyphenolicAerivative from Salvia miltiorrhiza Bunge, as aMultifunctional Agent for the Treatment of Alzheimer's Disease,Molecular Diversity2013, 17, 515-524.
  12. Jinggong Liu, Jun Qiu, Mingxue Wang,Ling Wang, Lijuan Su, Jinbo Gao,Jun Xu, Shi-Liang Huang,Lian-QuanGu, Zhi-Shu Huang,Ding Li.Synthesisand Characterization of 1H-Phenanthro [9,10-d]imidazole Derivatives asMultifunctional Agents for Treatment of Alzheimer's Disease.Biochim. Biophys. Acta. 2014,10, 2886-2903.
  13. Jun Xu, QiongGu, Haibo Liu, Jaiju Zhou,Xianzhang Bu, Zhishu Huang, Gui Lu, Ding Li, Dongqing Wei,Ling Wang, and LianquanGu. Chemomics and Drug Innovation,SCIENCE CHINA Chemistry2013,56, 71-85.
  14. Xiaoyong Wei, Dan Chen, Yanchun Yi, HuiQi, Xinxin Gao, Hua Fang, QiongGu,LingWang, LianquanGu.Syringic Acid Extracted from HerbadendrobiiPrevents Diabetic Cataract Pathogenesis by Inhibiting Aldose Reductase Activity.Evid. Based. Complement. Alternat. Med.2012. doi: 10.1155/2012/426537.
  15. Wenxia Zhao, QiongGu,LingWang, Hu Ge, Jiabo Li and Jun Xu.Three-dimensionalPharmacophore Modeling of Liver-1 X Receptor Agonists,J. Chem. Inf.Model.2011,51, 2147-2155.
  16. Yan Xin, Peng Ding, Liu Zhihong,Ling Wang, GuQiong, Xu Jun.BigData in Drug Design.Chin.Sci. Bull.2015, 60: 558–565.
  17. HangMa, Weixi Liu, Leslie Frost,LingWang, Liwen Kong, Joel A. Dain, Navindra P. Seeram.Thehydrolyzablegallotannin, penta-O-galloyl-β-D-glucopyranoside, inhibits theformation of advanced glycationendproducts by protecting protein structure.Mol. BioSyst.2015, 11(5):1338-1347.

發明專利

1.徐峻、王領、顧瓊一種β-苯丙氨酸類化合物作為醛糖還原酶抑制劑的套用,中國專利號:ZL201110377528.7(已授權)
2.董藝凝、王領、陳衛、徐峻、張灝、陳海琴一種耐熱β-半乳糖苷酶突變體的構建,中國專利號:ZL2011101770088.8 (已授權)
3.顧瓊、曹影影、王領、徐峻、巫瑞波丹酚酸A用於製備防治老年痴呆症藥物的套用,中國專利申請號:201310196330.8

相關詞條

熱門詞條

聯絡我們